Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Unvalidated PROs In Rare Diseases: US FDA May Have To ‘Work Through’ Them, CBER’s Marks Says
May 18 2023
•
By
Sue Sutter
FDA wants sponsors to use validated PROs but may have to accept unvalidated measures in the case of very rare diseases. • Source: Shutterstock
More from Rare Diseases
More from Pink Sheet